Fennec Pharmaceuticals INC

Fennec Pharmaceuticals shareholders approved all director nominees and corporate proposals at the 2026 annual meeting.

Fennec Pharmaceuticals has granted 50,000 stock options to three new employees under its 2026 Equity Inducement Plan.

Fennec Pharmaceuticals Inc. announced the upcoming retirement of a Board of Directors member and a reduction in the Board's size.

Fennec Pharmaceuticals announced that four abstracts evaluating its drug PEDMARK (sodium thiosulfate injection) have been accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting.

Fennec Pharmaceuticals announced the initiation of an investigator-sponsored study by the University of Arizona Cancer Center to evaluate PEDMARK's use in adult patients with head and neck and testicular cancers receiving cisplatin.

Fennec Pharmaceuticals announced record full-year 2025 net PEDMARK product sales of $44.6 million, a 50% year-over-year increase, alongside strategic business advancements and a strengthened financial position.

Fennec Pharmaceuticals announced first quarter 2026 results, with PEDMARK net sales reaching $15.1 million, a 73% increase year-over-year, driven by market penetration and sales force expansion.

Fennec Pharmaceuticals reported its strongest quarter in history with record net product sales of $12.5 million and its first profitable quarter from operations, driven by increased market penetration of PEDMARK.

Fennec Pharmaceuticals reports strong Q2 2025 net product sales growth of 33% for PEDMARK, driven by increased market penetration and AYA population focus, despite a net loss.

Fennec Pharmaceuticals reports an 18% year-over-year increase in total net revenues for the first quarter of 2025, driven by growth in PEDMARK sales and strategic focus.

Fennec Pharmaceuticals reported a net product sales of $7.0 million for Q3 2024, driven by increasing momentum in the Adolescent and Young Adult (AYA) segment and strategic leadership appointments.

Fennec Pharmaceuticals announced positive second quarter results with $7.3 million in net product sales and the appointment of a new CEO, Jeff Hackman.

Fennec Pharmaceuticals announced record net product sales of $44.6 million for fiscal year 2025, a 50% increase year-over-year, alongside the full redemption of its outstanding debt.

Fennec Pharmaceuticals reports a 40% increase in PEDMARK net product sales for FY2024, alongside strategic debt reduction and expansion into European markets.

Fennec Pharmaceuticals announced positive full-year 2023 financial results, highlighted by $21.3 million in PEDMARK net product sales and a significant licensing agreement for European commercialization.

Pierre Sargis Sayad, Chief Medical Officer of Fennec Pharmaceuticals Inc., received 168 shares of common stock on July 31, 2026.

Terry L Evans, Chief Commercial Officer of Fennec Pharmaceuticals Inc., received 168 shares of common stock on July 31, 2026.

Christiana Marie Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals Inc., received 156 shares of common stock on July 31, 2026.

Jeffrey S. Hackman, Chief Executive Officer and a Director of Fennec Pharmaceuticals Inc., received 1,159 shares of common stock on July 31, 2026.

Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals, reported a transaction involving the release of restricted shares.

Pierre Sargis, Chief Medical Officer at Fennec Pharmaceuticals, acquired 168 common shares on June 30, 2026, as shares were released from restriction.

Fennec Pharmaceuticals Inc. has issued its proxy statement for the Annual and Special Meeting of Shareholders scheduled for June 10, 2026, detailing proposals for director elections, auditor appointments, executive compensation votes, and equity plan amendments.

Fennec Pharmaceuticals is asking shareholders to approve amendments to its equity incentive plan, including increasing the number of shares available for issuance and adding an employee stock purchase program, at the annual meeting on June 3, 2025.

Fennec Pharmaceuticals will hold its annual shareholder meeting on June 25, 2024, to discuss audited financials, elect directors, appoint auditors, and conduct an advisory vote on executive compensation.

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 7.2% of Fennec Pharmaceuticals Inc. common shares.

Rosalind Advisors Inc. and related entities have reported beneficial ownership of approximately 8.8% of Fennec Pharmaceuticals Inc. common shares as of March 31, 2026.

AIGH Capital Management and affiliated entities now beneficially own 5.7% of Fennec Pharmaceuticals' common shares, as disclosed in a Schedule 13G filing.

Sonic Fund II, L.P., along with Sonic GP LLC and Lawrence Kam, reported an aggregate beneficial ownership of 8.2% of Fennec Pharmaceuticals Inc.'s common stock as of December 31, 2025.

Rosalind Advisors, Rosalind Master Fund, and associated individuals have reported beneficial ownership exceeding 9% in Fennec Pharmaceuticals Inc.

Southpoint Master Fund and related entities have reported an 8.0% beneficial ownership stake in Fennec Pharmaceuticals Inc., holding 2,744,741 common shares.